Shenzhen Jindu Biomedical Technology closes Series A for AI-for-life-sciences platform
What's the deal? Shenzhen Jindu Biomedical TechnologyDealroom has a profile for this one. Try Dealroom → (津渡生科), a Chinese startup building AI tools for life sciences, has closed its Series A round. Gaotejia InvestmentDealroom has a profile for this one. Try Dealroom → led the funding through its Gaotejia Xiamen Ruilu FundDealroom has a profile for this one. Try Dealroom →.
The company provides AI algorithm development, a cloud platform, and integrated training-inference hardware for researchers and industrial users. Its core product is Bioford, a platform built on a proprietary large language model called GeneLLM, which targets six key areas: medical diagnostics, drug development, biomanufacturing, biological breeding, environmental monitoring, and basic scientific research.
Jindu has built nine life sciences model libraries on top of GeneLLM, positioning it as an infrastructure layer for biological research and applications.
Why now? The intersection of AI and biology is one of the hottest investment themes globally. Foundation models trained on biological data — proteins, genomes, molecular structures — are proving useful across drug discovery, diagnostics, and agriculture. China's push for self-sufficiency in both AI and biotech makes a domestic platform play particularly timely.
The proceeds will go toward deepening R&D in frontier AI for life sciences, expanding market reach, and accelerating breakthroughs in both foundational biological research and industrial applications.
What could go wrong? The AI-for-biology space is getting crowded. Global players like Google DeepMind (with AlphaFold) and numerous well-funded startups are competing for the same use cases. Jindu will need to prove that GeneLLM delivers meaningful advantages over open-source alternatives and larger competitors with deeper pockets.
Serving six distinct verticals — from drug development to environmental monitoring — is ambitious for an early-stage company. Spreading resources too thin across such a broad scope could dilute focus and slow product-market fit in any single domain.
The signal: This deal reflects growing investor appetite for AI infrastructure tailored to specific scientific domains, rather than general-purpose models. As life sciences workflows become increasingly computation-heavy, startups that can bundle models, platforms, and hardware into integrated solutions stand to capture significant value — particularly in China, where the government is actively encouraging homegrown AI capabilities in strategic sectors.
Read more: ITJuzi
